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SUMMARY
Immune responses are essential for pathogen elimi-
nation but also cause tissue damage, leading to dis-
ease or death. However, it is unclear how the host im-
mune system balances control of infection and
protection from the collateral tissue damage. Here,
we show that PD-1-mediated restriction of immune
responses is essential for durable control of chronic
LCMV infection in mice. In contrast to responses in
the chronic phase, PD-1 blockade in the subacute
phase of infection paradoxically results in viral persis-
tence. This effect is associated with damage to
lymphoid architecture and subsequently decreases
adaptive immune responses. Moreover, this tissue
damage is type I interferon dependent, as sequential
blockade of the interferon receptor and PD-1 path-
ways prevents immunopathology and enhances con-
trol of infection. We conclude that PD-1-mediated
suppression is required as an immunoregulatory
mechanism for sustained responses to chronic viral
infectionbyantagonizing type-I interferon-dependent
immunopathology.
INTRODUCTION
The host immune system responds to invading pathogens
through a variety of effector mechanisms that not only control
infection but also cause host damage (Rouse and Sehrawat,
2010). Reduction of pathogen burden occurs primarily through
immune effector mechanisms, including expression of cytokines
and cytotoxic molecules (Ka¨gi et al., 1994; Samuel, 2001). How-
ever, elimination of pathogens often causes collateral tissue
damage, referred to as immunopathology, leading to significant
disease or death (Doherty and Zinkernagel, 1974; Graham et al.,
2005; Zinkernagel, 2005). Several regulatory mechanisms pre-
vent excessive immune activation and development of immuno-
pathology, including expression of inhibitory receptors and
cytokines, as well as the generation of regulatory immune cells
(Chen and Flies, 2013; Josefowicz et al., 2012; Moore et al.,
2001). Although immunoregulatory factors restrict effector re-
sponses, the long-term consequence of attenuated activity on
pathogen control is unclear.
The inhibitory receptor PD-1 is rapidly upregulated following
exposure of T cells to antigen (Ag) and remains high during exper-
imental infection of mice with rapidly replicating Lymphocytic
choriomeningitis virus (LCMV) strains, such as clone 13 (Ahn
et al., 2018; Barber et al., 2006). High Ag load results in decreased
CD8 T cell function, termed T cell ‘‘exhaustion,’’ and a long-term
viremia that is eventually resolved in amajority of immunocompe-
tent mice (Matloubian et al., 1994; Moskophidis et al., 1993).
A mechanistic link between PD-1-mediated inhibition of T cells
and viral persistence is exemplified by the inhibition of the PD-
1:PD-L1 interaction, which leads to ‘‘reinvigoration’’ of CD8
T cells and accelerates control of viremia (Barber et al., 2006;
Lee et al., 2015). Thus, engagement of PD-1 signaling compro-
mises viral control through attenuation of effector responses
after CD8 T cells are exposed to high viral load. In contrast, infec-
tion of Pdcd1/ orCd274(encoding PD-L1)/mice with LCMV-
c13 results in lethal immunopathology within several days after
infection (Barber et al., 2006; Frebel et al., 2012), indicating that
PD-1-dependent immune regulation is essential to restrict host
damage. Thus, PD-1-mediated attenuation of antiviral responses
by CD8 T cells is thought to be primarily an immunoregulatory
mechanism by which the infected host minimizes tissue damage
(Speiser et al., 2014), although the impact of the attenuated im-
munity on pathogen control remains unknown. These findings
collectively imply that the consequence of PD-1-mediated
regulation of immune responses depends on the context of
host-microbe interactions, such as microenvironmental cues
and inflammatory signals.
In this study, we sought to define the impact of PD-1 signaling
on long-term viral control and the contexts that modulate its
function in host-pathogen interactions. We found that loss of
PD-1 signals during the early stages of chronic viral infection re-
sults in long-term viral persistence. Defective antiviral immunity
resulted from atrophy of lymphoid tissues and global lymphope-
nia with marked loss of germinal center (GC) B cells due to
excessive T cell responses. Intriguingly, a transient blockade of
type I interferons (IFN-Is) not only reversed tissue damage
caused by PD-1 blockade but also enhanced viral clearance in
combination with a subsequent PD-1 blockade. Thus, functional
outcomes of the engagement or blockade of the PD-1 pathway
depend on inflammatory conditions established by IFN-Is, and
thus, the PD-1 pathway must be engaged not only for host
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protection against immunopathology but also for durable anti-
viral immunity.
RESULTS
PD-1 Blockade at the Peak of Viremia Enhances CD8 T
Cell Activation with No Immediate Impact on Viral
Control
Cd274/ mice die from immunopathology by infection with the
chronic LCMV-c13, but not the acute LCMV-Armstrong (LCMV-
Arm) strain (Barber et al., 2006). To determine whether high viral
load is sufficient to induce the lethal immunopathology in the
absence of PD-1 signaling, we infected C57BL/6 (B6) mice
with LCMV-c13 and blocked PD-1 by injecting anti-PD-L1
monoclonal antibody (mAb) on day 8 post-infection (dpi), corre-
sponding to the peak of viremia (Wherry et al., 2003). As a con-
trol, we infected B6 mice with LCMV-c13 and treated with
anti-PD-L1 at the time of infection, recapitulating lethal immuno-
pathology as shown using Cd274/ mice (Figure 1A; Barber
et al., 2006; Frebel et al., 2012). Depletion of CD8 T cells prior
to infection completely rescued the mice from death, although
depletion of CD4 T cells had little impact on their survival, con-
firming CD8 T-cell-dependent immunopathology (Figure S1A;
Frebel et al., 2012). Although overriding PD-1-mediated sup-
pression during the initial stages after infection achieved expan-
sion of Ag-specific CD8 T cells on 5 dpi, it had little impact on the
establishment of high viremia (Figures S1B–S1D), suggesting a
minimal role of PD-1 in controlling virus in this context.
In marked contrast, the majority of mice survived when anti-
PD-L1 treatment started on 8 dpi (Figure 1A), indicating that
high viral load is insufficient to cause death of the infected
mice. To rule out the possibility that the lack of death resulted
from resistance of target tissues or reduced Ag presentation,
we transferred unexhausted CD8 T cells harvested from
Figure 1. PD-1 Blockade at the Peak of Viremia Enhances CD8 T Cell Activation with No Immediate Impact on Viral Control
(A) Survival LCMV-c13-infected B6 mice following anti-PD-L1 treatment. n = 25 (control), n = 6 (days 0–8), and n = 30 (days 8–22) pooled from 3 experiments.
(B) Survival of LCMV-c13-infected B6 mice after adoptive transfer of unexhausted LCMV-specific CD8 T cells and treatment with anti-PD-L1 or isotype control.
Data are from 3 experiments.
(C) Expression of CD4, CD8, CD44, and LCMV-gp276-specific T cell receptor (TCR) in peripheral bloodmononuclear cells (PBMCs) from control and anti-PD-L1-
treated mice on 14 dpi with LCMV-c13 infection. Representative plots are shown with mean ± SD from 3 experiments.
(D and E) Expression of CD4, CD8, CD44, PD-1, LAG-3, and LCMV-gp33-specific TCR in PBMCs on 22 dpi. Representative plots (D) and mean ± SD from 2
experiments (E) are shown.
(F) Plasma viral RNA load in LCMV-c13-infected mice on 22 dpi. Data pooled from 5 experiments are shown with median. The statistical difference was tested by
the Mann-Whitney U test.
See also Figure S1.
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LCMV-Arm-infected mice into LCMV-c13-infected mice and
subsequently treated the recipient mice with anti-PD-L1. All
LCMV-c13-infected recipient mice died quickly after anti-PD-L1
treatment (Figure 1B), indicating that the resistance to lethal pa-
thology of mice treated with anti-PD-L1 on 8–22 dpi is indepen-
dent of T-cell-extrinsic resistance of the infected animals.
The increased frequency of total and LCMV-specific CD8
T cells in the peripheral blood on 14 dpi in mice with anti-PD-
L1 treatment started on 8 dpi indicated that virus-specific CD8
T cells are suppressed by PD-1 signaling during this period (Fig-
ure 1C). However, the increase in CD8 T cells was no longer
observed on 22 dpi with expression of PD-1 and LAG-3 by
LCMV-specific CD8 T cells being elevated in anti-PD-L1-treated
compared with control antibody-treated or untreated mice (Fig-
ures 1D and 1E). PD-1 blockade has been shown to promote
pathogen clearance in certain infection models, including
LCMV-c13 infection (Barber et al., 2006; Bhadra et al., 2011;
Fuller et al., 2013). However, plasma viral titers were unchanged
on day 22 dpi (Figure 1F). These results indicate that engage-
ment of the PD-1 pathway during the acute and subacute phases
has little immediate impact on control of viral infection.
PD-1 Signaling Protects Host from Sustained
Immunopathology in Lymphoid Organs
Although the majority of LCMV-infected mice treated with anti-
PD-L1 initiated on 8 dpi survived, we found a significant delay
in recovery of body weight, suggesting that PD-1 blockade dur-
ing this period causes non-lethal immunopathology (Figure S2A).
Lymphoid organs are transiently disrupted following LCMV-c13
infection due predominantly to T-cell-mediated tissue damage
(M€uller et al., 2002; Teijaro et al., 2013; Wilson et al., 2013; Zin-
kernagel et al., 1999). We thus determined whether excessive
loss of the integrity of lymphoid organs, presumably impacting
subsequent durable immunity, is a direct consequence of PD-1
blockade. Indeed, spleen sizes and splenocyte numbers in
anti-PD-L1-treated mice were significantly reduced compared
to controls (Figures 2A and 2B). Histological analyses of spleens
on 14 and 22 dpi revealed smaller B cell follicles and disrupted
red and white pulp boundaries in anti-PD-L1-treated animals
(Figures 2C and S2B). This tissue damage in the spleen was
CD8 T cell dependent because it was prevented by depletion
of CD8 T cells prior to infection (Figure S2C). Frequencies of
LCMV-specific CD8 T cells, including ‘‘terminally exhausted’’
PD-1+ TIM-3+ cells and stem-cell-like PD-1+ TCF-1+ cells (Im
et al., 2016; Utzschneider et al., 2016; Wu et al., 2016), were
similar in control and treatedmice (Figures 2D and 2E). However,
absolute numbers of these populations were diminished in pro-
portion to reductions in spleen size and cellularity (Figure 2E).
It has now become clear that the consequences of loss of PD-1
signaling differ depending on contexts in which the signal is
blocked. Although the blockade at later time points in LCMV
infection or in the tumor microenvironment enhances CD8 T cell
responses, its constitutive loss paradoxically leads to more pro-
nounced cell-intrinsic dysfunction of CD8 T cells (Barber et al.,
2006; Odorizzi et al., 2015). To determine whether intrinsic CD8
T cell function is altered by PD-1 blockade during the subacute
period, we analyzed cytokine production ex vivo and proliferative
capacity of CD8 T cells in vivo by adoptive transfer to congenic
mice followed by LCMV-c13 infection. Immediately following
blockade of PD-L1, we detected increased frequencies of tumor
necrosis factor alpha (TNF-a)+ interferon (IFN)-g+ co-producing
CD8 T cells ex vivo as well as an increased frequency of Ki-67+
LCMV-specific CD8 T cells (Figures 2F and 2G), suggesting
PD-1 blockade started on 8 dpi resulted in enhanced activity of
Ag-specific CD8 T cells. Additionally, adoptively transferred PD-
1+ CD8 T cells from control or anti-PD-L1-treated mice were
capable of comparable secondary expansion in the recipient
mice (Figure2H), indicating thatAg-specificCD8Tcellspreserved
polyfunctionality and proliferative capacity, regardless of PD-1
blockade during this period. These results suggest that the
decreased overall CD8 T cell response in the treated mice is sec-
ondary to tissue damage in lymphoid organs caused by CD8
T cells.
CD8 T cells also directly target Ag-specific B cells in LCMV
infection and thus impair antibody responses (Moseman et al.,
2016). We hypothesized PD-1 blockade exacerbates CD8
T-cell-dependent cytotoxicity to B cells. Consistently, despite
comparable frequencies of CD8 T cells and total B220+ B cells,
we observed a significant reduction in the frequencies and
numbers of GL7+ Fas+ GC B cells known to be directly infected
by LCMV (Moseman et al., 2016) as well as in anti-LCMV IgG2c
titers (Figures 2I and 2J). Although PD-1 blockade could also act
directly on B cells and cause their death by hyperactivation, we
did not detect PD-1 expression on B cells at this stage of infec-
tion, making this explanation unlikely (Figure S2D). Moreover,
depletion of CD8 T cells prior to infection restored GC B cell
numbers and anti-LCMV IgG2c titers (Figures S2E and S2F),
indicating that the GC B cell reduction was mediated by Ag-spe-
cific killing by uninhibited CD8 T cells. These data collectively
indicate that PD-1 signaling during the subacute stage of
LCMV infection protects hosts from excess tissue damage,
particularly in the lymphoid organs that provide a microenviron-
ment for proper adaptive immune responses. Thus, engagement
of the PD-1 pathway may be an essential component of protec-
tive immunity to control persistent viral infection targeting
lymphoid organs.
Engagement of PD-1/PD-L1 Is Essential for Control of
Chronic LCMV Infection
Wehave shown that PD-1 is necessary to prevent tissue damage
with no immediate impact on viral control. We thus hypothesized
that insufficient adaptive immunity resulting from the defective
lymphoid tissue integrity impairs long-term control of virus.
Accordingly, we conducted a longitudinal analysis of viremia
using different regimens of PD-1 blockade. As demonstrated
previously (Barber et al., 2006), PD-1 blockade late in the infec-
tion, initiated on 23 dpi, accelerated resolution of viremia, with
viral RNA undetectable by 50 dpi (Figure 3A, blue dots). In sharp
contrast, PD-1 blockade initiated on 8 dpi impaired viral control
with a majority of infected mice exhibiting viral persistence
(Figure 3A, red dots). Thus, PD-1 engagement in the subacute
phase of infection, after T cell priming and initial clonal expan-
sion, is required to preserve durable antiviral responses.
To further delineate the effects of a temporary PD-1 blockade
on 8–22 dpi, we first examined how function of Ag-specific CD8
T cells was impacted. It has been shown that loss of PD-1
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Figure 2. PD-1 Blockade at the Peak of Viral Load Results in Reduced Spleen Sizes and Pan-lymphopenia
(A) Gross images of spleens from control and anti-PD-L1-treated mice on 22 dpi.
(B) Splenocyte counts of control and anti-PD-L1-treated mice on 22 dpi. n > 8 mice per group, shown by mean and SD.
(C) H&E staining of spleen sections from control and day 8–22 anti-PD-L1-treatedmice on 22 dpi. Scale bars, 200 mm. Representative images of 6mice per group
are shown.
(D) Expression of CD44 and LCMV-gp33-specific TCR of total splenocytes and expression of TCF-1 and TIM-3 by LCMV-gp33-specific CD8 T cells in control and
anti-PD-L1-treated mice on 22 dpi.
(E) Statistical analysis of frequencies and absolute numbers of the indicated cell populations pooled from 2 experiments. n = 4–6 mice per group.
(F) Expression of IFN-g and TNF-a by splenocytes from LCMV-c13-infected control and anti-PD-L1-treated B6 mice following stimulation with the gp276-284
peptide. Representative data from 2 experiments are shown with mean ± SD; n = 4.
(G) Expression of Ki-67 by gp33-specific CD8 T cells.
(H) Frequencies of CD45.2 PD-1+ donor CD8 T cells in PBMCs of CD45.1-recipient mice that received PD-1+ CD8 T cells from LCMV-c13-infected anti-PD-L1-
treated B6 mice and subsequently challenged with LCMV-c13. Data are pooled from two experiments.
(I) Expression of Fas and GL7 expression in B220+ splenocytes from control and anti-PD-L1-treated mice. Data from 2 experiments are shown with mean
and SD.
(J) Anti-LCMV IgG2c antibody titers on 22 dpi.
See also Figure S2.
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signaling depletes T-bet+ CD8 T cells, resulting in defective
antiviral responses (Odorizzi et al., 2015). To this end, similar to
analysis on 22 dpi, frequencies of LCMV-specific CD8 T cells,
including those of PD-1+ TCF-1+ and T-bet+ CD8 T cells, were
comparable between 8–22 dpi treated and control groups in
the spleen on 37 dpi (Figures 3B and 3C). However, expression
of TIM-3 by Ag-specific CD8 T cells in the spleen was increased
in the treated mice (Figures 3B and 3C), suggesting an accumu-
lation of severely exhausted cells due to the changes in the
microenvironment. This change of CD8 T cells in the spleen
was reflected by more pronounced reduction of both total and
LCMV-specific CD8 T cells in the peripheral blood (Figure 3D).
Thus, it is likely that the decline in CD8 T cells and diminished
anti-LCMV antibody responses led to defective viral control in
mice treated with anti-PD-L1 between 8–22 dpi. Together, our
results indicate that engagement of the PD-1 pathway in the
face of persistent Ag is essential for durable antiviral responses
by generating requisite numbers of adaptive immune cells
through the maintenance of lymphoid tissue integrity.
IFN-Is Are Required for Anti-PD-L1-Mediated
Immunopathology
Our results demonstrate the requirement of PD-1 signaling
for protecting the host from tissue damage that compromises
antiviral responses. However, immunopathology preferentially
occurred during early time points in the infection, potentially
due to elevated inflammatory cytokines. Among the cytokines
induced upon viral infection, IFN-Is are transiently produced
through by plasmacytoid dendritic cells (pDCs) and other
myeloid cells upon infection by LCMV-c13 (Macal et al., 2012;
Teijaro et al., 2013; Wang et al., 2012; Wilson et al., 2013; Ng
et al., 2015). The expression of IFN-Is peaks in the acute stage
and would thus be consistent with their roles in enhancing
immunopathology following anti-PD-L1 treatment in the acute
phase (Baccala et al., 2014; Oldstone et al., 2018). To first
test whether IFN-Is were required for lethal immunopathology
in LCMV-c13-infected mice resulting from PD-1 blockade, we
combined administration of blocking mAbs against interferon
alpha/beta receptor 1 (IFNAR) immediately before infection
Figure 3. Engagement of PD-1 in the Subacute Phase Is Required for Durable Control of LCMV Infection
(A) Plasma viral RNA load in LCMV-c13-infected B6 mice treated with anti-PD-L1 on 8–22 dpi (red dots, same as Figure 1) or 23–37 dpi (blue dots). Data are
pooled from 5 experiments shown with median.
(B–D) Expression of CD4, CD8, CD44, PD-1, LAG3, and LCMV-gp33-specific TCR by splenocytes (B and C) and peripheral bloodmononuclear cells (D) on day 37
of LCMV-c13 infection. Representative plots are shown with median ± SD from at least 2 experiments.
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(day 1) and PD-L1 on 0–8 dpi. In striking contrast to mice
treated with anti-PD-L1 alone, almost all infected mice were
rescued from death by the co-treatment (Figure 4A), indicating
that IFN-Is enhance effector function of Ag-specific CD8
T cells.
We next examined how loss of IFNAR signaling impacted the
CD8 T cell response to LCMV-c13 infection. We found reduced
frequencies of total and LCMV-specific CD8 T cells in peripheral
blood on 8 dpi in anti-IFNAR-treated mice (Figure 4B). This
diminished CD8 T cell expansion was independent of natural
killer (NK)-cell-dependent cytotoxicity, as CD8 T cell frequencies
remained unchanged with depletion of NK cells (Crouse et al.,
2014; Madera et al., 2016; Xu et al., 2014; Figure S3A). In
Ifnar1/ mice, splenocyte counts were increased by two-fold,
consistent with diminished CD8 T-cell-mediated tissue damage,
although total and LCMV-specific CD8 T cell numbers were
reduced (Figures S3B–S3E). Among LCMV-specific CD8
T cells, we observed skewed differentiation into TCF-1+ mem-
ory-like CD8 T cells over TIM-3+ effector/exhausted cells (Fig-
ures S3B–S3E), consistent with a previous study (Wu et al.,
2016). These results suggest that differentiation of activated
CD8 T cells into effectors is suppressed in the absence of
IFNAR signaling. In addition, LCMV-specific CD8 T cells
deprived of IFNAR signaling expressed substantially higher
PD-1 compared to control CD8 T cells (Figure 4B) and there-
fore may be more sensitive to PD-L1-mediated suppression.
Figure 4. Type I Interferon Receptor Blockade Rescues Immunopathology Caused by Loss of PD-1 Signaling in LCMV-Infected Mice
(A) Survival of LCMV-c13-infected B6 mice treated with anti-IFNAR 1 day prior to infection, anti-PD-L1 (days 0, 2, 4, 6, and 8), or both. Data pooled from 3
experiments with n > 6 mice per group are shown.
(B and C) Frequencies of total CD8 T cells, LCMV-gp33-specific CD8 T cells, and PD-1+ cells in indicated PBMC populations on 8 dpi in LCMV-c13-infected B6
mice with indicated treatment. Representative plots (B) with mean ± SD from 2 experiments (C) are shown.
(D) Plasma LCMV viral RNA load in LCMV-c13-infected B6 mice with indicated treatment from 2 experiments shown with median.
(E) Macroscopic images of spleen and splenocyte counts of LCMV-c-13-infected B6mice with indicated treatment as in (A) on 22 dpi. Data from two experiments
are shown.
See also Figures S3 and S4.
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Consistently, additional blockade of PD-1 signaling rescued the
reduction in LCMV-specific CD8 T cells without impacting total
CD8 T cell frequencies (Figures 4B and 4C).
We next sought to establish which cellular compartments IF-
N-Is target to cause immunopathology. Bone marrow (BM) chi-
meras reconstituted with Ifnar1/ hematopoietic cells died
following LCMV-c13 infection and anti-PD-L1 treatment with
similar kinetics to control chimeric mice reconstituted with
wild-type (WT) BM cells (Figure S4A). Although Ifnar1/ host
mice reconstituted with Ifnar1/ hematopoietic cells were resis-
tant to PD-1-blockade-mediated death as expected, Ifnar1/
hosts reconstituted with WT BM cells also succumbed to PD-1
blockade following LCMV-c13 infection (Figure S4B). These re-
sults collectively indicate that IFN-Is program enhanced CD8
T cell effector responses by acting on both non-hematopoietic
and hematopoietic cells and in part by restricting induction of
PD-1 in activated CD8 T cells to desensitize them to PD-L1-
mediated suppression.
To determine whether early PD-1 blockade can promote con-
trol of infection in the absence of excess tissue damage, we
tracked antiviral responses following anti-IFNAR and anti-PD-
L1 treatment. As shown previously (Teijaro et al., 2013; Wilson
et al., 2013), anti-IFNAR alone on day1 prior to infection accel-
erated resolution of viremia compared to control (Figure 4D).
The viral control was further enhanced by combination of anti-IF-
NAR on day1 with anti-PD-L1 on 8 dpi. In contrast, anti-IFNAR
administration on 7 dpi, at which time IFN-Is are already unde-
tectable in serum (Macal et al., 2012; Teijaro et al., 2013; Wang
et al., 2012; Wilson et al., 2013), had no effect (Figure 4D).
Consistently, atrophy of the spleen caused by anti-PD-L1 was
completely rescued in mice co-treated with anti-IFNAR and
anti-PD-L1 (Figure 4E). These results suggest IFN-Is as a target
to tune the outcomes of immune checkpoint blockade.
DISCUSSION
Our data demonstrate a critical, temporal function of PD-1 in the
regulation of host immunity against persistent infections. PD-1 is
a major inhibitory receptor that causes attenuated CD8 T cell re-
sponses to some infections and tumors. Blockade of the PD-1/
PD-L1 interaction to restore function of exhausted CD8 T cells
was originally demonstrated using a mouse chronic LCMV infec-
tion model and has now been applied broadly as a cancer immu-
notherapy in humans. However, the biological significance of
PD-1-mediated suppression on long-term control of persistent
viral infection is understudied. We now demonstrate that PD-1-
mediated restriction of T cell responses is beneficial for control
of chronic infection.
Immunopathology in the LCMV-c13 infection model is a
consequence of abundant and broad expression of viral Ag
across different cell types. LCMV is a non-cytopathic virus,
and the pathogenesis of LCMV infection is predominantly
host T cell response dependent, as is the case with some viral
infections in humans, such as hepatitis B virus (HBV), HCV,
and HIV infections. Context-dependent PD-1-mediated pro-
tection through restriction of immunopathology may be bene-
ficial to establish durable immunity against those infections,
although the benefit of restraining host T cell responses may
not be applicable to all viral infections. Constitutive absence
of PD-1 signal causes severe exhaustion of CD8 T cells in a
cell-intrinsic manner (Odorizzi et al., 2015). In contrast, our re-
sults show the requirement for PD-1 to preserve CD8 T cell
responses in a T-cell-extrinsic manner and thus reveal the
additional role of immune regulation in durable antiviral immu-
nity. Collectively, restriction of CD8 T cell function by PD-1 or
acquisition of the exhausted state is a host protective mecha-
nism in response to persistent Ag, for which long-term durable
immunity is prioritized at the expense of immediate immune
responses.
Our results also show that IFN-Is enhance immunopathology
in the setting of PD-1/PD-L1 deficiency. Sequential blockade
of IFNAR and PD-1 signaling synergistically improved control
of LCMV infection, further supporting our conclusion that pre-
venting initial immunopathology is critical for overall antiviral re-
sponses, even if it temporarily compromises viral control.
Although IFNAR is broadly expressed in both hematopoietic
and non-hematopoietic compartments, its expression in either
compartment was sufficient to cause lethal immunopathology
in LCMV-c13-infected mice depleted of PD-1 signaling. IFNAR
signaling thus likely contributes to maximizing CD8 T cell re-
sponses through multiple mechanisms, including effector differ-
entiation and modulation of PD-1 expression by CD8 T cells.
Although blockade of IFNAR signaling enhances control of
persistent LCMV infection (Teijaro et al., 2013; Wilson et al.,
2013), the therapeutic effects appear to be mediated by regula-
tion of CD8 T cells and preservation of host immune functions,
similar to PD-1-mediated suppression, rather than direct
enhancement of T cell function. This conclusion is supported
by protection of LCMV-specific B cells by IFNAR blockade (Fallet
et al., 2016; Moseman et al., 2016). The IFN-I pathway could be
a potential target for modulation of immunotherapies against
infections and cancer beyond its direct effect on the virus or
transformed cells.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-B220-FITC Biolegend CAT#103206; RRID:AB_312991
Anti-B220-PB Biolegend CAT#103227; RRID:AB_492876
Anti-CD4-BV605 Biolegend CAT#100451; RRID:AB_2564591
Anti-CD44-AF700 Biolegend CAT#103026; RRID:AB_493713
Anti-CD8a-BUV395 BD CAT#563786; RRID:AB_2732919
Anti-CD8a-FITC Biolegend CAT#100706; RRID:AB_312745
Anti-CD8b-PerCP-Cy5.5 Biolegend CAT#126610; RRID:AB_2260149
Anti-EOMES-PerCP-e710 Invitrogen CAT#46-4875-82; RRID:AB_10597455
Anti-Fas-PE-Cy7 BD CAT#557653; RRID:AB_396768
Anti-IFNg-PE Biolegend CAT#505808; RRID:AB_315402
Anti-Ki-67-APC BD CAT#561126; RRID:AB_10611874
Anti-LAG-3-BV421 Biolegend CAT#125221; RRID:AB_2572080
Anti-mouse IgG2c-biotin SOUTHERN BIOTECHNOLOGY CAT#1077-08; RRID:AB_2794453
Anti-PD1-PE-Cy7 Biolegend CAT#135216; RRID:AB_10689635
anti-Rabbit-IgG-A488 Invitrogen CAT#A27034; RRID:AB_2536097
Anti-T-bet-APC Biolegend CAT#644814; RRID:AB_10901173
Anti-TCF-1 CST CAT#2203S; RRID:AB_2199302
Anti-TIM3-BV421 Biolegend CAT#119723; RRID:AB_2616908
Anti-TNFa-APC Biolegend CAT#506308; RRID:AB_315429
GL7-A647 Biolegend CAT#144606; RRID:AB_2562185
Streptavidin-HRP BD CAT#554066
Anti-CD4 (for In vivo administration) Leinco CAT#C1333; RRID:AB_2737452
Anti-CD8 (for In vivo administration) Leinco CAT#C2442
Anti-IFNAR (for In vivo administration) Leinco CAT#I-401; RRID:AB_2491621
Anti-NK1.1 (for In vivo administration) Leinco CAT#N123; RRID:AB_2737553
Anti-PD-L1 (for In vivo administration) BioXcell CAT#BE0101; RRID:AB_10949073
Isotype control (for In vivo administration) BioxCell CAT#BE0090; RRID:AB_1107780
Bacterial and Virus Strains
LCMV-Armstrong Marco Colonna’s Lab N/A
LCMV-clone 13 Marco Colonna’s Lab N/A
Chemicals, Peptides, and Recombinant Proteins
Brefeldin A Biolegend CAT#420601
H2-Db (LCMV gp33-41) tetramer MBL International CAT#TB-5002-1
H2-Db(LCMV gp276-284) tetramer MBL International CAT#TB-5009-1
Fetal Bovine Serum Thermofisher CAT#10437028
LCMV gp276-284 peptide Genscript CAT#RP19983
LCMV gp33-41 peptide Genscript CAT#RP20257
Linear Acrylamide Ambion CAT#AM9520
LIVE/DEAD Aqua Invitrogen CAT#L34966
RPMI-1640 Thermofisher CAT#SH3009601
TMB Substrate Dako Dako CAT#T03026
Critical Commercial Assays
Foxp3/transcription factor staining buffer Thermofisher CAT#00-5523-00
Luminaris Color HiGreen qPCR Master Mix Thermofisher CAT#K0394
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LEAD CONTACT AND MATERIALS AVAILABILITY
This study did not generate new reagents. Further information and requests for resources and reagents should be directed to and will
be fulfilled by the Lead Contact, Takeshi Egawa (egawat@wustl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Male C57BL/6N and B6-CD45.1 mice were purchased from Charles River Laboratory. Ifnar1–/– were obtained from Michael S. Dia-
mond (Washington University). All mice were housed in a specific pathogen-free facility at Washington University in St. Louis, and
were used at 8 to 10 weeks of age, unless stated otherwise. We used both males and females except that only male mice were
used as recipient mice for bone marrow chimeras to minimize the risk of graft rejection due to the male antigen. All experiments
were performed according to a protocol approved by Washington University’s Animal Studies Committee.
METHOD DETAILS
Mouse Infection and Viral Load Quantification
Stocks of LCMV were made by propagating virus in BHK (baby hamster kidney) cells, followed by titering of culture supernatants by
focus forming assay on Vero (African green monkey kidney) cells. For LCMV infection, mice were infected with 23 105 plaque-form-
ing units (PFU) of LCMV-Arm via the intraperitoneal route or 2 3 106 (PFU) of LCMV-c13 by intravenous injection. For the quantifi-
cation of plasma viral load, RNA was extracted from 10 mL of plasma using Trizol (Life Technologies). Before RNA extraction a
spike-in of exogenous control mRNA encoding clover was added to the plasma samples as previously described. The amounts
of the LCMV gp transcript relative to that of ‘spiked- in’ clover RNA were determined by real-time qRT-PCR using qScript cDNA syn-
thesis and Luminaris HiColor GreenMaster Mix as previously described (Chou et al., 2016; McCausland and Crotty, 2008; Raju et al.,
2018).
Antibody treatments
200 mg of anti-PD-L1 (29F.1.G2, BioXcell) was injected every day or every other day for treatments initiated on day 0, otherwise
administration was every three days for a full two weeks of treatment. anti-IFNAR (MAR1, Leinco) was intraperitoneally injected at
the indicated time points after infection at a dose of 1 mg. For depletion of CD4 T cells, 200 mg of anti-CD4 (GK1.5, Leinco) was in-
jected on day1 and +1 of infection. For depletion of CD8 T cells, 400 mg of anti-CD8 (YTS-169, Leinco) was injected on a day before
infection. For NK cell depletion, 100 mg of anti-NK1.1 (PK136, Leinco) was injected on a day before infection.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Negative Selection CD8 Kit Biolegend CAT#480008
qScript cDNA SuperMix Quantabio CAT#95048-100
Experimental Models: Cell Lines
BHK cells Marco Colonna’s Lab N/A
Vero Cells Marco Colonna’s Lab N/A
Experimental Models: Organisms/Strains
B6-CD45.1 Charles River CAT#564
C57BL/6NCr Charles River CAT#556
Ifnar1–/– Michael Diamond’s Lab N/A
Oligonucleotides
GFP FWD primer: GACAACCACTACCTGAGCCA Raju et al., 2018 N/A, Sigma Custom Synthesis
GFP REV primer: GTCCATGCCATGTGTAATCC Raju et al., 2018 N/A, Sigma Custom Synthesis
LCMV gp FWD primer: CATTCACCTGGACTTTGTCAGACTC McCausland and Crotty, 2008 N/A, Sigma Custom Synthesis
LCMV gp REV primer: GCAACTGCTGTGTTCCCGAAAC McCausland and Crotty, 2008 N/A, Sigma Custom Synthesis
Software and Algorithms
Prism, version 8 Graphpad https://www.graphpad.com/scientific-
software/prism/
Flowjo, version 10 FlowJo, LLC https://www.flowjo.com/
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Histology
Organs were fixed in 4% PFA overnight, then dehydrated in 70% ethanol. Samples were subject paraffin embedding and H&E stain-
ing using standard methods performed by the Developmental Biology Histology Core at Washington University in St. Louis. Images
were collected using an EVOS FL Auto Imaging System (Thermofisher).
Cell Preparation, Staining, and Flow Cytometry
Single-cell suspensions were prepared by manual disruption of spleens with frosted glass slides. Absolute live cell counts were
determined by Trypan-blue exclusion using Vi-Cell (Beckman Coulter). Tetramer staining was performed using iTag-PE LCMV
gp33-44 and gp276-284 (MBL international) for 1 hour at RT followed by surface staining was performed at 4C for 30 minutes.
For intracellular cytokine staining, splenocytes were cultured in RPMI-1640 supplemented with 10% fetal bovine serum in the
presence of 1 ug/ml of LCMV-gp peptide (Genscript) and 5 ug/ml of Brefeldin A (Biolegend) for 4 hours. Cells were stained for
surface makers and then subject to LIVE/DEAD Aqua staining (Thermofisher) for 30 minutes at 4C before being fixed with 4%
PFA for 10 minutes at RT. Cells were then washed twice with 0.03% saponin in 2% FBS/PBS before being stained with the indicated
antibodies in 0.3%Saponin in 2%FBS/PBS for 20min at 4C. Staining for transcription factors was performed using the Foxp3 stain-
ing kit (eBioscience) according to the manufacturer’s instructions. Stained samples were analyzed with FACS LSR Fortessa or X20
(BD) and data processing with FlowJo Software (FlowJo. LLC).
Anti-LCMV antibody ELISA
Anti-LCMV antibody ELISA was performed as described previously (Raju et al., 2018). Briefly, Nunc Polysorp plates were coated with
10ug/mL sonicated cell lysate from LCMV-infected BHK-21 cells as capture antigen or uninfected BHK-21 cell lysate overnight
followed by UV irradiation (300 mJ in Stratalinker 1800; Stratagene). Plasma antibody was detected with biotinylated anti-mouse
IgG2c antibody (1077–08; Southern Biotech), followed by Streptavin-HRP (BD), and TMB substrate (Dako). Endpoint titers were
calculated by a sigmoidal-dose response curve using Graphpad Prism software.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using Prism (Graphpad Software). P-values were calculated with an unpaired two-tailed
Student’s t test or the Mann-Whitney U-test for two-group comparisons and by one-way ANOVA for multi-group comparisons
with the Tukey post hoc test. *p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
DATA AND CODE AVAILABILITY
This study did not generate code or new datasets.
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Figure S1. Anti-PD-L1 treatment initiated on day 0 of LCMV-c13 infection results in expansion of CD8 T 
cells with no impact on viral titer. Related to Figure 1.  (A) Survival of LCMV-c13 infected mice that were 
treated with anti-PD-L1 on day 0 in the absence of CD4+ or CD8+ cells. (B and C) Expression of CD4, CD8a, 
CD44, PD-1, and gp33-specific TCR in peripheral blood mononuclear cells of B6 mice on 5dpi of LCMV-c13 
with the indicated treatments. Representative plots (B) and data pooled from 3 experiments with n>4 mice per 
group shown with mean±SD (C). (D) Plasma LCMV gp transcripts in LCMV-c13-infected B6 mice with indicated 
antibody treatment on 5 dpi. Data were pooled from 2 independent experiments and shown with median. Statistical 
analysis tested with the Mann-Whitney U-test.  
  
Figure S2. Non-lethal immunopathology following anti-PD-L1 treatment initiated on 8 dpi. Related to 
Figure 2.  (A) Change in body weight following LCMV-c13 infection in control and B6 mice with anti-PD-L1 
treatment initiated on 8 dpi. (B) Hematoxylin and eosin staining of spleen sections from control and day 8-22 anti-
PD-L1-treated B6 mice on 14 dpi and 22 dpi as indicated. Scale bars indicate 400 µm. Images are representative 
of greater than 6 mice per group. (C) Splenocyte counts and gross appearance of the spleen of LCMV-c13 infected 
B6 mice on 22 dpi with treatment with anti-PD-L1 or anti-PD-L1+anti-CD8. (D) Expression of PD-1 by Fas+ 
GL7+ GC B cells, non-GC B cells and CD8 T cells in LCMV-c13 infected B6 mice on 22 dpi. (E and F) Absolute 
numbers of Fas+ GL7+ GC B cells in the spleen and anti-LCMV IgG2c antibody titers in the serum of LCMV-c13 
infected, anti-PD-L1-treated B6 mice on 22 dpi. Data are pooled from two experiments with n>4 mice per group 
and shown with mean±SD.   
  
 
Figure S3. Ifnar1–/– mice display increased spleen size, but diminished CD8 T cell responses on 8 dpi of 
LCMV-c13. Related to Figure 4.  (A) Frequencies of total and LCMV gp33-specific CD8 T cells in peripheral 
blood mononuclear cells on 22 dpi in Ifnar1–/– mice treated with anti-NK1.1 antibody. Data pooled from 2 
experiments and shown with mean±SD. (B and C) Splenocyte counts (B) and expression of indicated molecules 
or tetramer binding by splenocytes (C) of Ifnar1+/+ (WT, top) and Ifnar1–/– (bottom) mice on 8 dpi. Representative 
plots with the frequencies of cells in each gated population are shown. (D and E) Frequencies (D) and absolute 
numbers (E) of indicated populations in the spleen on 8 dpi pooled from 2 experiments and shown with mean±SD.  
  
 
Figure S4. IFNAR signaling in either the hematopoietic or non-hematopoietic compartment is sufficient to 
cause lethal immunopathology. Related to Figure 4.  Survival of Ifnar1+/+ (A) and Ifnar1–/– (B) bone marrow 
(BM) chimeras reconstituted with Ifnar1+/+ (WT) or Ifnar1–/– hematopoietic cells after infection with LCMV-c13 
and treatment with anti-PD-L1 at the beginning of infection as indicated. Data are representative of two 
experiments with 5 mice in each group.  
